AstraZeneca completes acquisition of Pearl Therapeutics

28th Jun 2013 07:02

FTSE 100-listed biopharmaceutical business AstraZeneca has completed the acquisition of Pearl Therapeutics, a California-based company focused on the development of inhaled small-molecule therapeutics for respiratory disease. Upon completion of the merger, AstraZeneca acquired 100% of Pearl's shares. AstraZeneca reported that the deal would give it access to a potential new treatment for chronic obstructive pulmonary disease (COPD), currently in late-stage development, and inhaler and formulation technology that would provide a platform for future combination products.MF